Ultralife (ULBI) to Release Earnings on Thursday

Ultralife (NASDAQ:ULBI - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Thursday, July 24th. Analysts expect Ultralife to post earnings of $0.14 per share and revenue of $51.00 million for the quarter.

Ultralife (NASDAQ:ULBI - Get Free Report) last released its earnings results on Friday, May 9th. The technology company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.02). The company had revenue of $50.75 million for the quarter, compared to analysts' expectations of $54.50 million. Ultralife had a net margin of 3.05% and a return on equity of 4.61%. During the same quarter last year, the firm posted $0.21 earnings per share.

Ultralife Stock Performance

NASDAQ ULBI traded down $0.14 on Friday, hitting $8.69. 38,520 shares of the company traded hands, compared to its average volume of 73,716. The company has a market capitalization of $144.54 million, a price-to-earnings ratio of 27.16 and a beta of 1.00. The company has a current ratio of 3.22, a quick ratio of 1.70 and a debt-to-equity ratio of 0.37. The business's 50 day moving average price is $7.52 and its 200-day moving average price is $6.58. Ultralife has a 52-week low of $4.07 and a 52-week high of $12.40.

Insider Buying and Selling at Ultralife

In other news, Director Bradford T. Whitmore bought 16,063 shares of the stock in a transaction dated Wednesday, May 14th. The shares were acquired at an average cost of $5.47 per share, with a total value of $87,864.61. Following the purchase, the director directly owned 1,045,947 shares in the company, valued at $5,721,330.09. The trade was a 1.56% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Thomas Louis Saeli purchased 5,000 shares of the firm's stock in a transaction that occurred on Wednesday, May 14th. The stock was bought at an average cost of $5.44 per share, for a total transaction of $27,200.00. Following the completion of the purchase, the director directly owned 85,000 shares in the company, valued at $462,400. This represents a 6.25% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 47,140 shares of company stock worth $256,355. 40.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Ultralife stock. Jones Financial Companies Lllp increased its position in shares of Ultralife Corporation (NASDAQ:ULBI - Free Report) by 1,428.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,287 shares of the technology company's stock after purchasing an additional 14,287 shares during the period. Jones Financial Companies Lllp owned 0.09% of Ultralife worth $82,000 at the end of the most recent quarter. 30.68% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Wall Street Zen raised Ultralife from a "buy" rating to a "strong-buy" rating in a research note on Friday, June 6th.

About Ultralife

Ultralife Corporation, together with its subsidiaries, designs, manufactures, installs, and maintains power, and communication and electronics systems worldwide. The company operates in two segments, Battery & Energy Products and Communications Systems. The Battery & Energy Products segment offers lithium 9-volt, cylindrical, thin lithium manganese dioxide, rechargeable, and other non-rechargeable batteries; lithium-ion cells, multi-kilowatt module lithium-ion battery systems, and uninterruptable power supplies; and rugged military and commercial battery charging systems and accessories, including smart chargers, multi-bay charging systems, and various cables.